Bright minds unite to improve stroke and dementia care
Innovative medical research in stroke and dementia will be outlined at a community event presented by Western Australia’s Perron Institute...
Continue reading
This website may not work correctly in Internet Explorer. We recommend switching to a more secure modern web browser such as Microsoft Edge which is already installed on your computer.
Research group
Arpitha Chikkanna is a PhD candidate currently working on designing novel Antisense Oligonucleotides (ASOs) as a therapeutic option for chronic kidney conditions. In patients with these conditions, kidney metabolism is not as efficient as in normal individual. To elaborate on this, Arpitha is designing and fine-tuning the ASOs to target the hallmark gene of the disease. She hopes to achieve a lead candidate that can improve kidney metabolism thereby benefits the patients therapeutically.
Keep informed with our latest updates.
Stay up to date with our latest news and announcements.